The global impact of drug resistance

被引:76
作者
Howard, DH
Scott, RD
Packard, R
Jones, D
机构
[1] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA
[2] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA USA
[3] Johns Hopkins Univ, Dept Hist Sci Med & Technol, Baltimore, MD USA
[4] Johns Hopkins Univ, Dept Hist, Baltimore, MD USA
[5] Univ Alabama, Univ Hosp, Dept Drug Informat, Birmingham, AL USA
关键词
D O I
10.1086/344656
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Measuring the impact of drug resistance is an important step in understanding the scope of the problem and formulating policies to limit the emergence and spread of resistant organisms. Studies have focused on measuring the increased costs, morbidity, and mortality in patients with infections due to resistant versus susceptible organisms. These have generally found that resistance worsens outcomes. By focusing only on infected patients, however, they may understate the impact of resistance. It is important to recognize that resistance also affects the treatment of individuals with nonresistant organisms. In areas with high rates of resistance, physicians and governments have changed empiric therapy for malaria, tuberculosis, acute respiratory infections, and other diseases, increasing overall treatment costs. In some instances, these costs may exceed those attributable to treatment failure.
引用
收藏
页码:S4 / S10
页数:7
相关论文
共 45 条
  • [1] Abramovicz M., 1999, MED LETT DRUGS THER, V41, P95
  • [2] Nosocomial methicillin-resistant and methicillin-susceptible, Staphylococcus aureus primary bacteremia:: At what costs
    Abramson, MA
    Sexton, DJ
    [J]. INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 1999, 20 (06) : 408 - 411
  • [3] [Anonymous], GLOBAL IMPACT DRUG R
  • [4] [Anonymous], 1993, Private Choices and Public Health: The AIDS Epidemic in an Economic Perspective
  • [5] Bartlett John G., 2000, Clinical Infectious Diseases, V31, P347, DOI 10.1086/313954
  • [6] BECERRA M, 1999, GLOBAL IMPACT DRUG R, P107
  • [7] BOLAND PB, 1997, LANCET, V350, P1624
  • [8] Evaluating treatment protocols to prevent antibiotic resistance
    Bonhoeffer, S
    Lipsitch, M
    Levin, BR
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (22) : 12106 - 12111
  • [9] Control of endemic methicillin-resistant Staphylococcus aureus -: A cost-benefit analysis in an intensive care unit
    Chaix, C
    Durand-Zaleski, I
    Alberti, C
    Brun-Buisson, C
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (18): : 1745 - 1751
  • [10] Changes in antimicrobial resistance among Salmonella enterica serovar typhimurium isolates from humans and cattle in the northwestern United States, 1982-1997
    Davis, MA
    Hancock, DD
    Besser, TE
    Rice, DH
    Gay, JM
    Gay, C
    Gearhart, L
    DiGiacomo, R
    [J]. EMERGING INFECTIOUS DISEASES, 1999, 5 (06) : 802 - 806